| abstract |
The present invention provides a composition effective for a pathological condition in which inhibition of androgen receptor and / or PI3Kβ is beneficial, such as cancer. An androgen receptor inhibitor, 4- (3- (4-cyano-3- (trifluoromethyl) phenyl) -5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1- Yl) -2-fluoro-N-methylbenzamide and the PI3Kβ inhibitor 2-methyl-1-{[2-methyl-3- (trifluoromethyl) phenyl] methyl} -6- (4-morpholinyl)- A pharmaceutical composition comprising both 1H-benzimidazole-4-carboxylic acid. [Selection] Figure 1 |